Code intelligence

FDA-NDA208969 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA208969.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: REXTOVY (NALOXONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA208969 · Infectious Disease

High

REXTOVY (naloxone hydrochloride), a nasal spray, will likely fall under Medicare Part D for oral drugs, as it is not injectable and thus not eligible for Part B billing. Billing teams should consider

View alert